CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-17). The draft was written by AI, the existence of all 4 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 404 · Search date 2026-07-17 · Methodology v0.6

Weissella cibaria JW15,
does it really help with Enhanced immune function and defense against infection?

30-Second Summary
C
Evidence Grade C · 47 · Safety caution
Increased NK-cell activity is not the same outcome as infection prevention
What the
research shows
In a double-blind RCT of 100 participants, JW15 at 1×10^10 CFU/day for eight weeks increased NK-cell activity, while IFN-γ and IgG1 did not change significantly. The study did not test whether colds or infections were reduced, and evidence from one strain, one trial, and immune surrogate markers supports C.
What the
ads claim
Immune enhancement, viral defense, and cold prevention are distinct claims. The trial directly supports only NK-cell activity under specified assay conditions.
*

Useful facts when choosing a product

  • Original recognition 2022-20 coexists with duplicate recognition 2022-35 for the same ingredient.
  • The daily intake is JW15 1×10^10 CFU; strain identity and guaranteed viable count matter.
  • People with illness or immune vulnerability need professional advice.
Gap Measurement · Verdict 404 · C 47
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Lee 2018 randomized 100 nondiabetic adults to JW15 at 1×10^10 CFU/day or placebo for eight weeks and analyzed 82. NK-cell activity increased, but IFN-gamma and IgG1 did not change significantly, and infection incidence was not measured. Funding came from a Rural Development Administration program. The same ingredient has both the original recognition number 2022-20 for the National Institute of Agricultural Sciences and duplicate recognition number 2022-35 for Huons Foodience.

02

Why this is classified as C (47)

A strain-specific 100-participant RCT exists, but evidence is one trial using NK-cell surrogate markers without clinical infection outcomes, supporting C with 47 points.

Counterpoint. A positive human signal remains for the immune-marker subclaim, but it does not extend to defense against infection.

Rejudgment record. Reassessment (cross-check reflected) — A publicly funded RCT analyzed 82 of 100 participants; only the NK-cell surrogate was positive, IFN-gamma and IgG1 were null, and infection incidence was not measured

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Improvement of immune markers (NK cells)CSurrogate marker only
Protection against actual infections?Infection incidence was not measured

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Lee et al. 20188-week randomized double-blind placebo-controlled trial82Rural Development Administration cooperative research programNK-cell activity, cytokines, and immunoglobulinsNK-cell activity increased, but IFN-γ and IgG1 were not significant and infection incidence was not assessed.Key
Jang et al. 2021Phenotypic and genomic strain-safety assessment15Rural Development AdministrationAntibiotic resistance, hemolysis, toxic metabolites, and virulence genesSupports candidate-probiotic safety characterization, not clinical immune efficacy.Safety only
§

Receipt — 4 References

All 4 cited sources were verified for existence at the original page (as of 2026-07-17).

Lee YJ, Lee A, Yoo HJ, Kim M, Noh GM, Lee JH. Supplementation with the probiotic strain Weissella cibaria JW15 enhances natural killer cell activity in nondiabetic subjects. J Funct Foods. 2018;48:153-158. DOI: 10.1016/j.jff.2018.07.009. ClinicalTrials.gov: NCT03209635.
checked
Jang YJ, Gwon HM, Jeong WS, Yeo SH, Kim SY. Safety Evaluation of Weissella cibaria JW15 by Phenotypic and Genotypic Property Analysis. Microorganisms. 2021;9(12):2450. DOI: 10.3390/microorganisms9122450.
checked
Ministry of Food and Drug Safety. Weissella cibaria JW15 Probiotics, duplicate individually recognized ingredient 2022-35. November 22, 2022. No PMID or DOI.
checked
Ministry of Food and Drug Safety. Weissella cibaria JW15 Probiotics, original individually recognized ingredient 2022-20. May 24, 2022. No PMID or DOI.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-17 · Corrections: none

Cite this verdict

Weissella cibaria JW15 x enhanced immune function and defense against infection Evidence Grade C card
[Chamgap] Weissella cibaria JW15 x enhanced immune function and defense against infection — Evidence Grade C·47. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/weissella-cibaria-jw15-immunity-infection-defense/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.